Miracle Mile Advisors’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-25,000
| Closed | -$591K | – | 527 |
|
|
2023
Q4 | $591K | Hold |
25,000
| – | – | 0.02% | 320 |
|
|
2023
Q3 | $373K | Hold |
25,000
| – | – | 0.01% | 370 |
|
|
2023
Q2 | $274K | Hold |
25,000
| – | – | 0.01% | 430 |
|
|
2023
Q1 | $218K | Hold |
25,000
| – | – | 0.01% | 469 |
|
|
2022
Q4 | $157K | Hold |
25,000
| – | – | 0.01% | 482 |
|
|
2022
Q3 | $88K | Hold |
25,000
| – | – | ﹤0.01% | 429 |
|
|
2022
Q2 | $74K | Hold |
25,000
| – | – | ﹤0.01% | 429 |
|
|
2022
Q1 | $78K | Hold |
25,000
| – | – | ﹤0.01% | 455 |
|
|
2021
Q4 | $85K | Sell |
25,000
-25,000
| -50% | -$94.9K | ﹤0.01% | 440 |
|
|
2021
Q3 | $183K | Buy |
50,000
+25,000
| +100% | +$98.5K | 0.01% | 403 |
|
|
2021
Q2 | $111K | Hold |
25,000
| – | – | 0.01% | 372 |
|
|
2021
Q1 | $114K | Hold |
25,000
| – | – | 0.01% | 368 |
|
|
2020
Q4 | $144K | Hold |
25,000
| – | – | 0.01% | 357 |
|
|
2020
Q3 | $89K | Hold |
25,000
| – | – | 0.01% | 345 |
|
|
2020
Q2 | $87K | Hold |
25,000
| – | – | 0.01% | 300 |
|
|
2020
Q1 | $37K | Hold |
25,000
| – | – | ﹤0.01% | 270 |
|
|
2019
Q4 | $49K | Buy |
+25,000
| New | +$93.9K | ﹤0.01% | 295 |
|
Other funds holding CBAY
Miracle Mile Advisors's CBAY Position: Q1 2024 in Review
Miracle Mile Advisors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 25,000 shares — an estimated $591K sold.
Miracle Mile Advisors first reported a position in CBAY in Q4 2019 and held it in 17 quarters. The position peaked at $591K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- Miracle Mile Advisors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- Miracle Mile Advisors sold 25,000 Cymabay Therapeutics shares in Q1 2024, an estimated $591K.
- Miracle Mile Advisors first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 17 quarters.
- Miracle Mile Advisors's Cymabay Therapeutics position peaked at $591K in Q4 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on Miracle Mile Advisors's 13F filing for Q1 2024, filed 18 Apr 2024.